Over 1,000 Chemotherapy Protocols And Counting

Phase 3, double-blind, placebo-controlled trial (LAURA) Locally advanced, unresectable stage III NSCLC with EGFR exon 19 deletion or L858R mutation after chemoradiation Osimertinib

27 Aug

Non-Small Cell Lung Cancer

New Drug: Lazertinib for EGFR mutated NSCLC

Type: Phase 3, international, randomized trial Population: Patients with previously untreated EGFR-mutated advanced NSCLC (Ex19del or L858R) Treatment: Amivantamab–lazertinib vs.

24 Jun

Small Cell Lung Cancer

New Drug: Tarlatamab for SCLC

Phase 2, open-label (DeLLphi-301) Relapsed/refractory to platinum-based therapy Advanced SCLC Tarlatamamab 10 or 100 mg => Final dose selected as 10 mg

22 Jun

Mesothelioma

New Reference: Pembrolizumab with CISplatin and PEMEtrexed in Mesothelioma

J Clin Oncol 2023 41:17_suppl, LBA8505 Chu QS IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleur

20 Nov

Multiple Myeloma

New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma

Lancet Haematol 2023 Oct;10(10):e825-e837 Voorhees PM Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagno

13 Jan

Non-Small Cell Lung Cancer

New Drug: Amivantamab for NSCLC

Phase 3, international, randomized trial (PAPILLON) Advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy Amivantamab + Chemoterapy (n=153) vs.

12 Dec

Breast Cancer

New Protocol: Eribulin for Breast Cancer

J Clin Oncol 2015;33(6):594-601 Kaufman PA Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast can

21 Jun

Small Cell Lung Cancer

New Indication: Repotrectinib for NTRK-Fusion Positive Solid Tumors

Advanced NTRK-fusion+ solid tumors (TRIDENT-1) TKI-naive (n=40) and TKI-pretreated (n=48)

21 Jun

Non-Small Cell Lung Cancer

New Drug: Repotrectinib for ROS1-fusion positive NSCLC

Phase 1-2 single-arm (TRIDENT-1) ROS1-fusion positive advanced NSCLC TKI-naive (n=71) - prior-TKI (n=56)

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries